The trajectory of companies tied to Sildenafil's history presents a challenging investment scenario . While the initial boom generated substantial profits , generic competition have significantly diminished market share . Investing in associated pharmaceutical firms now requires a thorough assessment of proprietary rights , evolving patient shifts